Cargando…

Enhanced CT-based radiomics predicts pathological complete response after neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction: a two-center study

PURPOSE: This study aimed to develop and validate CT-based models to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) for advanced adenocarcinoma of the esophagogastric junction (AEG). METHODS: Pre-NAC clinical and imaging data of AEG patients who underwent surgical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Wenpeng, Li, Liming, Liu, Siyun, Chen, Yunjin, Liu, Chenchen, Han, Yijing, Wang, Fang, Zhan, Pengchao, Zhao, Huiping, Li, Jing, Gao, Jianbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385906/ https://www.ncbi.nlm.nih.gov/pubmed/35976518 http://dx.doi.org/10.1186/s13244-022-01273-w

Ejemplares similares

Potential Value of Radiomics in the Identification of Stage T3 and T4a Esophagogastric Junction Adenocarcinoma Based on Contrast-Enhanced CT Images
por: Chang, Xu, et al.
Publicado: (2021)

Application of computed tomography-based radiomics in differential diagnosis of adenocarcinoma and squamous cell carcinoma at the esophagogastric junction
por: Du, Ke-Pu, et al.
Publicado: (2022)

Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis
por: Li, Jing, et al.
Publicado: (2021)

Prognostic impact of sarcopenia in patients with locally advanced adenocarcinoma of the esophagogastric junction treated with neoadjuvant chemoradiotherapy
por: Ming, Jiao, et al.
Publicado: (2023)

ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS
por: de CASTRO, Juliana Silveira Lima, et al.
Publicado: (2021)

Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
por: Laxague, Francisco, et al.
Publicado: (2021)

The Value of Predicting Human Epidermal Growth Factor Receptor 2 Status in Adenocarcinoma of the Esophagogastric Junction on CT-Based Radiomics Nomogram
por: Wang, Shuxing, et al.
Publicado: (2021)

Integrative proteomic characterization of adenocarcinoma of esophagogastric junction
por: Li, Shengli, et al.
Publicado: (2023)

The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction
por: Jomrich, Gerd, et al.
Publicado: (2018)

Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction
por: Cai, Ming-Zhi, et al.
Publicado: (2019)

Current surgical treatment of esophagogastric junction adenocarcinoma
por: Zhang, Shun, et al.
Publicado: (2019)

Nomogram predicted survival of patients with adenocarcinoma of esophagogastric junction
por: Zhou, Zhangjian, et al.
Publicado: (2015)

Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma
por: Li, Haijun, et al.
Publicado: (2017)

Investigation of BTLA tagging variants with risk of esophagogastric junction adenocarcinoma
por: Tang, Weifeng, et al.
Publicado: (2019)

Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study
por: Xu, Haitao, et al.
Publicado: (2020)

Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis
por: SCHULZE, BJÖRN, et al.
Publicado: (2014)

Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
por: Gebauer, Florian, et al.
Publicado: (2023)

The Early Diagnostic Value of Serum Interleukin-8 in Esophagogastric Junction Adenocarcinoma
por: Li, Zheng, et al.
Publicado: (2021)

Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma
por: Nobel, Tamar, et al.
Publicado: (2019)

Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S‐1 for clinical stage III gastric or esophagogastric junction adenocarcinoma
por: Kurokawa, Yukinori, et al.
Publicado: (2022)

Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma
por: Xu, Yi-Wei, et al.
Publicado: (2018)

Clinical Comparison of Endoscopic Ultrasonography and CT in Preoperative TN Staging of Esophagogastric Junction Cancer
por: Peng, Tao, et al.
Publicado: (2022)

Prognostic significance of NFIA and NFIB in esophageal squamous carcinoma and esophagogastric junction adenocarcinoma
por: Yang, Bo, et al.
Publicado: (2018)

Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial
por: Shi, Jinming, et al.
Publicado: (2022)

Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction
por: Tian, Yuan, et al.
Publicado: (2021)

Prognostic Importance of the Preoperative Naples Prognostic Score for Patients With Adenocarcinoma of the Esophagogastric Junction
por: Xiong, Jianping, et al.
Publicado: (2020)

Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China
por: Zhang, Hao, et al.
Publicado: (2013)

Clinical Efficacy of Endoscopic Submucosal Dissection for Adenocarcinomas of the Esophagogastric Junction
por: Nagami, Yasuaki, et al.
Publicado: (2014)

Can proximal Gastrectomy Be Justified for Advanced Adenocarcinoma of the Esophagogastric Junction?
por: Sato, Yuya, et al.
Publicado: (2018)

MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction
por: Just, Christina, et al.
Publicado: (2019)

Analysis of N(6)-Methyladenosine Methylome in Adenocarcinoma of Esophagogastric Junction
por: Huang, Jia-Bin, et al.
Publicado: (2022)

Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction
por: Zheng, Yi-Han, et al.
Publicado: (2022)

Esophagogastric junctional neuroendocrine tumor with adenocarcinoma: A case report
por: Kong, Zhen-Zhen, et al.
Publicado: (2022)

The correlation between the margin of resection and prognosis in esophagogastric junction adenocarcinoma
por: Pang, Tao, et al.
Publicado: (2023)

Post-neoadjuvant chemoradiotherapy tumor resectability following induction chemotherapy in locally advanced proximal gastric and adenocarcinoma of the esophagogastric junction: A clinical trial
por: Aledavood, Seyed Amir, et al.
Publicado: (2021)

Selection of Digestive Tract Reconstruction After Partial Gastric Sparing Surgery in Patients With Adenocarcinoma of the Esophagogastric Junction of cT(2)-T(3) Stage
por: Zhang, Junli, et al.
Publicado: (2022)

SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma
por: OuYang, Li-Ying, et al.
Publicado: (2022)

Impacts of neoadjuvant therapy on the number of dissected lymph nodes in esophagogastric junction cancer patients
por: Wang, Qi, et al.
Publicado: (2023)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction
por: Sun, Lidan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aq6svhir85crue441q1s041a64